Can-Fite Biopharma Ltd., of Petach Tikva, Israel, said the phase II liver cancer trial testing namodenoson (CF-102) has enrolled and randomized all 78 patients. The study, which enrolled patients with advanced hepatocellular carcinoma (HCC), is measuring overall survival as the primary endpoint. Secondary endpoints include progression-free survival, safety and the relationship between outcomes and A3AR expression. Namodenoson is an oral, small molecule designed to bind to the A3 adenosine receptor and has orphan status in the U.S. and Europe and fast track status in the U.S. for second-line HCC.